Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Eli Lilly just became the first pharmaceutical company ever valued above $1 trillion, yet analysts who dig into its pipeline are arguing the market still has not grasped what the next two years could look like for shareholders.
A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have finally crossed the line from promising to proven.
By Avinash P and Purvi Agarwal Aug 19 (Reuters) - The main U.S. stock indexes were on track to open higher on Wednesday after a tech-led selloff in the previous session as investors assessed fresh
A successful cancer vaccine would be an important new market for Moderna, whose investors have been impatient for it to expand beyond its Covid prevention vaccine.
The Phase 3 trial tested Intismeran Autogene with Merck’s blockbuster immunotherapy Keytruda.
Moderna skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday.
Stock Market Today: The Dow Jones index rises Wednesday ahead of the Fed minutes. Nvidia supplier SK Hynix jumps on a stock buyback.
Investing.com - Investing.com -- U.S. stock futures edged lower in Asian trading on Wednesday, pointing to a cautious start on Wall Street after major indexes closed lower for a third consecutive session, as a global bond selloff and elevated oil prices kept investors wary and pressured rate-sensitive technology stocks.
Shares of US vaccine-maker Moderna soared 60 per cent in pre-market trading after the company reported successful results for a melanoma cancer...
An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said. Shares in Moderna jumped about 10% premarket, while Merck also climbed around 6%.
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
A successful cancer vaccine would be an important new market for Moderna, whose investors have been impatient for it to expand beyond its Covid prevention vaccine.
↗️ SK Hynix (SKHY, KR:000660): The chip giant announced plans for a $28 billion buyback. Its U.S.-listed shares jumped in premarket trading. Earlier, its Korean shares closed nearly 10% lower amid a selloff in Asia.
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
In early August 2026, Merck reported second-quarter sales of US$16,607 million and a net loss of US$1,335 million, raised its 2026 sales outlook, and advanced its pipeline with ENFLONSIA label expansion filings for high-risk young children and a new KEYTRUDA combination approval for muscle-invasive bladder cancer in Canada. These developments underline how Merck is pairing broadening product indications and oncology approvals with higher full-year sales guidance despite recent losses on its...
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
Zoetis (NYSE:ZTS) is an animal health company. Michael Burry is long the stock, several media outlets reported, citing his Substack disclosures. The stock is down about 40% so far this year. Let’s break down whether it’s worth buying. Why Burry Likes It Burry’s pitch is simple. Zoetis has dropped more than 70% from its 2021 […]
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.
They have businesses built to handle the toughest environments.
Roku, Merck & Co and Charles Schwab shares jumped to 52-week highs, extending strong earnings momentum, as well as gaining from company-specific analysts.
